A hidden tradeoff in Trump’s drug pricing deals

The government has announced “most-favored-nation” pricing agreements with 26 pharma companies. But the deals could stymie other plans to lower the country’s spending on prescription drugs.

By Kelly Bilodeau • Sept. 22, 2026

Novo talks up drug launches in effort to win back investors

At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products. 

By Jonathan Gardner • Sept. 21, 2026

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

How J&J paved the way for Compass’ coming psychedelic drug launch

In an interview with BioPharma Dive, Compass executives said that, should the FDA approve their treatment, they hope to capitalize on a strategy pioneered by J&J in selling the ketamine spray Spravato.

By Jacob Bell • Sept. 21, 2026

Mid-cap biotechs join Trump’s latest round of drug pricing deals

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.

By Jonathan Gardner • Sept. 1, 2026

Revolution pancreatic cancer drug should quickly become a blockbuster, analysts say

Rasonque’s $39,800 monthly list price surpassed Wall Street forecasts and led to rosier sales projections ahead of what one analyst described as a “historic” launch.

By Kristin Jensen • Aug. 27, 2026

New Jazz cancer drug approval could drive blockbuster sales

Ziihera can now be used as an initial treatment for all HER2-positive gastroesophageal adenocarcinomas, dramatically expanding the drug’s market potential.

By Jonathan Gardner • Aug. 25, 2026

[Podcast] (Season 2) The Progress Profile: Alzheimer’s Research in Focus

This podcast explores how leading Alzheimer’s experts are working to bridge the gap between clinical trial design and frontline care.

By BioPharma Dive's studioID • Aug. 24, 2026

How cost and perception could reshape the GLP-1 market

As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.

By Kelly Bilodeau • Aug. 21, 2026

Regeneron to challenge Ipsen as FDA clears bone disease drug

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

By Jonathan Gardner • Aug. 20, 2026

FDA nod is just the first hurdle for Moderna’s potential blockbuster flu vax

Strain selection timing and mRNA skepticism could limit the impact of Moderna’s game-changing mRNA flu shot.

By Alexandra Pecci • Aug. 17, 2026

Lilly files six lawsuits in bid to shut down ‘black market’ for retatrutide

Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.

By Kristin Jensen • Aug. 12, 2026

Regulatory operations: The overlooked half of submission readiness

Submission readiness extends beyond content. Early regulatory operations planning supports a compliant, high-quality application.

Aug. 10, 2026

Erica Schwartz confirmed as next CDC director

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure as HHS chief. 

By Kristin Jensen • Aug. 6, 2026

Lilly climbs, Novo falls as obesity drug battle intensifies

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed analyst expectations.

By Kristin Jensen • Aug. 5, 2026

Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.

By Delilah Alvarado , Ben Fidler • Aug. 5, 2026

FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims & Hers hit back, calling the claims “baseless.”

By Jill Hughes • July 30, 2026

Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

By BioPharma Dive staff • July 29, 2026

Novo sues Lilly, alleging ‘misleading’ advertising of obesity drugs

The lawsuit follows a cease-and-desist request and argues Lilly is using “deceptive” ads to claim its GLP-1 products are broadly superior to Novo’s medicines. Lilly countered that its campaign is “truthful.”

By Jonathan Gardner • July 21, 2026

Novartis climbs on upbeat drug sales as key readouts loom

A return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.

By Kristin Jensen • July 21, 2026

Compounders maintain a firm grip on the GLP-1 market

Despite an FDA crackdown, numerous pharma lawsuits and possible safety risks, nearly 1 in 5 patients are still taking cheaper weight-loss alternatives.

By Kelly Bilodeau • July 17, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026

Hospitals irate after Eli Lilly follows through on 340B ultimatum

The drugmaker stopped paying 340B discounts to hospitals that didn’t comply with its new paperwork requirements late last week. Hospitals are urging HRSA to step in.

By Rebecca Pifer Parduhn • June 23, 2026

From episodes to a lifetime: How AI can enable women’s health brands to build a partnership that lasts

Women's health audiences have long memories and finely tuned instincts for what is performative.

By Jennifer M. Barrett, MSc • June 22, 2026

Medicare drug price rule may target under-the-skin Keytruda and Opdivo

For 2029, a federal rule proposes closing a "loophole" that protects medicines transitioning from intravenous administration from price protection.

By Jonathan Gardner • June 15, 2026

Generic drugmakers gain key victory in ‘skinny label’ patent case

The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.

By Jonathan Gardner • June 5, 2026